Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation
Authors:
Open Access
- 8 April 2026
- journal article
- research article
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Abstract
Pancreatic cancer is an aggressive malignancy with poor prognosis and limited treatment options. Recent advances in immunotherapy have shown potential for improving outcomes; however, therapeutic resistance remains a challenge. We demonstrate that HAS2 is significantly upregulated in pancreatic cancer, and is associated with poor prognosis, reduced infiltration of CD4⁺ and CD8⁺ T cells, and shorter survival. Mechanistically, HAS2 stabilizes PD-L1, a key immune checkpoint molecule, by modulating K6- and K63-linked ubiquitination, enhancing PD-L1 stability and suppressing immune responses. Our study further reveals that HAS2 activates the AKT signaling pathway to downregulate March4 expression, a critical E3 ubiquitin ligase that negatively regulates PD-L1 stability, thereby promoting PD-L1 stabilization. In vivo, HAS2 knockout in KPC mice reduces PD-L1 levels, increases March4 expression, enhances T cell infiltration, and delays cancer progression. Reduced collagen deposition in HAS2⁺/⁻ tumors further underscores its role in tumor microenvironment remodeling. Targeting the HAS2-March4-PD-L1 axis through HAS2 inhibition, anti-PD-L1 therapy, or March4 overexpression suppresses tumor growth and improves survival.Keywords
Funding Information
- National Natural Science Foundation of China (82073372)
- National Natural Science Foundation of China (82372682)
This publication has 30 references indexed in Scilit:
- PD-L1: From cancer immunotherapy to therapeutic implications in multiple disordersMolecular Therapy, 2024
- Breaking the stromal barrier in pancreatic cancer: Advances and challengesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023
- Pancreatic cancer: Advances and challengesCell, 2023
- Role of K63-linked ubiquitination in cancerCell Death Discovery, 2022
- IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal AdenocarcinomaGastroenterology, 2022
- Stromal hyaluronan accumulation is associated with low immune response and poor prognosis in pancreatic cancerScientific Reports, 2021
- Pancreatic cancer stroma: an update on therapeutic targeting strategiesNature Reviews Gastroenterology & Hepatology, 2020
- Ubiquitin modificationsCell Research, 2016
- PD-L1-specific T cellsCancer Immunology, Immunotherapy, 2016
- K63-linked ubiquitination and neurodegenerationNeurobiology of Disease, 2011